99% High Purity Api Raw Material CAS 56-54-2 Quinidine Powder

99% High Purity Pharmaceutical Raw Materials Weight Losing Raw Materials Quinidine CAS 56-54-2

Product Name: Quinidine
Synonym: (8R,9S)-6'-Methoxycinchonan-9-ol;6-METHOXY-A-(5-VINYL-2-QUINUCLIDINYL)-4-QUINOLINE-METHANOL;CONCHININE;CONQUININE;B-QUININE;(+)-QUINIDINE;QUINIDINE;(+)-QUINDINE
CAS: 56-54-2
MF: C20H24N2O2
MW: 324.42
EINECS: 200-279-0

Related categories: Antibiotics, alkaloids; Chinese herbal medicine ingredients; cell signaling and neurobiology; APIs; antiarrhythmic drugs; cell biology; chiral; Alkaloids; Alkoxyquinolines; plant extracts; cardiovascular and cerebrovascular research raw materials; pharmaceutical intermediates; Raw materials; intermediates; Biochemistry; for Resolution of Acids; Optical Resolution; Quinoline Alkaloids; Quinolines; Synthetic Organic Chemistry; Intermediates & Fine Chemicals; Pharmaceuticals; Cinchona Alkaloids Monovalent Ion Channels; Chiral Catalysts, Ligands, and Reagents; Other Sodium Channel Modulators; Privileged Ligands and Complexes; Sodium Channel Modulators; Chiral Reagents; Heterocycles; DURAQUIN
Melting Point: 168-172 °C(lit.)

Specific Rotation: 256 º (c=1, EtOH)

Boiling Point: 462.75°C (rough estimate)

Density: 1.1294 (rough estimate)

Refractive Index: 1.5700 (estimate)

Storage Conditions: Store at -20°C

PKa: 5.4, 10.0(at 20℃)

Optical Activity: α]20/D +265±5°, c = 0.8% in ethanol (dry matter)

Water solubility: 0.05 g/100 mL (20 ºC)

Sensitivity: Light Sensitive

Stability: Stable. Incompatible with strong oxidizing agents.
Appearance: white powder

Description:

Quinidine is an antiarrhythmic drug. It is commonly used in its sulfates but also in the hydrochloride and gluconate salts. Quinidine sulphate is a white crystalline powder, odorless, very bitter taste, melting point 175 ~ 176 ° C, soluble in water, slightly soluble in ethanol.
Quinidine is an alkaloid extracted from the bark of the genus Cinchona ledgeriana (Moens). It has a direct effect on the cell membrane, mainly inhibits the transmembrane movement of sodium ions, and is self-disciplined and conductive to the heart. Both stress and contractility have direct inhibitory effects, and both have anticholinergic effects on the heart. It is suitable for the treatment and prevention of atrial fibrillation, atrial flutter, supraventricular and ventricular tachycardia, and the treatment and prevention of malignant premature beats.
Quinidine is the right-handed body of quinine, which has similar pharmacological properties, but quinidine is 5 to 10 times stronger than quinine in the heart, and it binds to the lipoprotein of the sodium channel on the myocardial cell membrane, making the channel The gate narrows to prevent Na+ inflow, resulting in a decrease in the depolarization speed of the 0 phase and a slower conduction. The myocardial self-discipline is reduced due to the slowing of the depolarization rate of the fourth phase, and the ectopic rhythm point is suppressed. Slow down the 3-phase K+ outflow to extend the refractory period. It also inhibits myocardial contractility and has anti-parasympathetic and sympathetic effects. Quinidine blocks the alpha receptor and causes blood vessels to dilate, especially when intravenously, causing a sharp drop in blood pressure, so it cannot be administered intravenously.
The above information was compiled by Andy editor of ChemicalBook.

Application:

It has anticholinergic effect and can induce ventricular arrhythmia, that is, syncope.

Class IA antiarrhythmic drug; potassium channel blocker; also used as a chiral catalyst.

The pharmacological effects of quinidine against arrhythmia mainly extend the myocardial refractory period, reduce myocardial stress, self-discipline and conductivity, and are used to treat atrial or ventricular tachycardia, to convert atrial flutter and atrial fibrillation. And prevent its recurrence. In the use of quinidine, due to different causes and individual differences, the amount of quinidine treatment and tolerance in different cases are also inconsistent. Hyperthyroidism, chronic atrial fibrillation, and significant enlargement of the heart are more tolerated. Long-term heart failure, bundle branch block, coronary heart disease tolerance is low, sometimes the general treatment volume causes poisoning, although quinidine poisoning is related to the size of the dose, but a small amount of individual cases can lead to arrhythmia. It is currently considered to be the inhibitory effect of quinidine on conduction, which can induce the reentry agonism of the diseased myocardium. In order to reduce quinidine poisoning, changes in heart rate, rhythm, blood pressure and electrocardiogram must be strictly observed during the medication.

Usage and dosage:

Oral: 0.2g per day on the first day, once every 2 hours, 5 times, if there is no obvious adverse reaction, the next day increased to 0.3 g each time, 0.4 g on the third day, every 2 hours 1 Once, for 5 times, the daily total should not exceed 2 g. After returning to normal heart rhythm, change the amount to 0.2 to 0.4 g per day. If the patient is ineffective for 3 to 4 days or has adverse reactions, the drug should be discontinued. Children should be given a test dose of 2 mg/kg. If there is no adverse reaction, start treatment after 1-2 hours. On the first day, each time 6 mg/kg, once every 2 hours, take 4 to 5 times; if the effect is not obvious There is no symptoms of poisoning. On the second day, you can continue to use the original amount or increase the original amount by 20%. If necessary, the original amount can be maintained on the third day.
Intravenous or intravenous drip: 0.25 g each time, diluted to 50 ml with 5% glucose injection, and slowly injected. In children, the first dose is 2 mg/kg, diluted with 100 ml of 5% glucose injection, and then instilled for 1 hour. If there is no allergic reaction, each time 6 mg/kg, once every 3 hours, 1 day The total amount does not exceed 30 mg/kg.